Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
URMC / Research / Clinical Trials / Study Details

Prostate Cancer: Cisplatin in Prostate Cancer

Research Question:
Can cisplatin once per week be safely combined with enzalutamide daily and will it result in a decline in PSA and shrinkage of known deposits of prostate cancer?

Basic Study Information

If you choose to participate in this study, you will receive cisplatin once per week for 6 weeks and you will continue to receive leuprolide and enzalutamide. You will also have blood samples collected at enrollment, 3 weeks, 5 weeks, and conclusion of treatment for research purposes.

Location: Cancer Center
Study Web URL:
Study Reference #: UGUP17050

Lead Researcher (Principal Investigator)

Lead Researcher:  Deepak Sahasrabudhe, MD

Study Contact Information

Study Coordinator: Ayesha Khan
Phone: (585) 275-3351

Additional Study Details

Learn More About These Conditions

More information about Prostate Cancer

Return to Search